HVT

Onymos and Vapotherm Announce Partnership to Create an End-to-End Internet of Medical Things Solution (IoMT)

Retrieved on: 
Wednesday, March 20, 2024
Temperature, Logic, Organization, Partnership, Internet of things, Fraction of inspired oxygen, VAPO, Patient, SAN, Gateway, Internet, Hospital, HVT, IoMT, HIPAA, OTCQX, Data, Periodic breathing, SOC 2

SAN FRANCISCO, March 20, 2024 /PRNewswire/ -- Onymos, developer of the world's first Features-as-a-Service platform, and Vapotherm, Inc. (OTCQX: VAPO), ("Vapotherm"), a global medical technology company whose proprietary high-velocity therapy® products treat patients of all ages suffering from respiratory distress, today announced the formation of a development and commercialization partnership. This partnership will help Vapotherm create a unique respiratory digital platform to meet its data visualization and device management goals for the Vapotherm HVT® 2.0 system in the acute care space as well as for future products in the home.

Key Points: 
  • Through the Onymos Features-as-a-Service platform , Vapotherm accesses Onymos' suite of Internet of Things (IoT) features — including Onymos Edge, Onymos Access, and Onymos DataStore — to build a secure end-to-end solution to connect the HVT 2.0 fleet with the cloud.
  • It consists of a GoLang-based "Gateway" application, an Angular web dashboard for remote device management, and cloud storage for patient data.
  • The Onymos platform also supports many of the other most popular frameworks for web and mobile application development.
  • For more information on Onymos, its Features-as-a-Service platform, or how it can help your company realize its IoT or IoMT goals, visit Onymos.com .

Vapotherm's HVT 2.0 System Overcomes Regulatory Hurdles for Entry into South America's Largest Health Care Market

Retrieved on: 
Thursday, February 29, 2024
VAPO, Intensive care medicine, Social media, Hospital, Compressed air, USD, Ageing, Periodic breathing, HVT, Vapotherm, Health, Patient, Optimism, OTCQX, COPD, Pharmaceutical industry

With the approval and subsequent launch of HVT 2.0 in Brazil, we look forward to establishing ourselves as a frontline solution in Latin America."

Key Points: 
  • With the approval and subsequent launch of HVT 2.0 in Brazil, we look forward to establishing ourselves as a frontline solution in Latin America."
  • These features facilitate optimal patient care in the most advanced hospitals as well as resource constrained environments.
  • With the approval of the new system in Brazil, Vapotherm is launching a new Portuguese website and social media campaign.
  • The Company attended in the XXVIII Brazilian Congress of Intensive Care Medicine, the largest event of its kind in Latin America, to collaborate with approximately three thousand clinicians.

Vapotherm Educates over 8,000 Clinicians in Respiratory Care Month

Retrieved on: 
Tuesday, November 28, 2023
Respiratory Care Week, VAPO, HVT, Hospital, NYSE, Patient, Vapotherm, Health, Education, Nursing

The education was free to clincians in celebration of Respiratory Care Week, and continued through the month of October culminating in the American Association for Respiratory Care Congress 5-8 November.

Key Points: 
  • The education was free to clincians in celebration of Respiratory Care Week, and continued through the month of October culminating in the American Association for Respiratory Care Congress 5-8 November.
  • Dr. Jessica Whittle, Chief Medical Officer at Vapotherm, shared her enthusiasm: "About 7,000 clinicians initially registered for our educational programs, and we are thrilled that even more participated as the value became more well-known.
  • Vapotherm is committed to partnering with clinicans to provide the highest level of patient care.
  • Dr. Whittle and Joe Army were both present at the American Association for Respiratory Care Congress to celebrate this accomplishment and educate about the HVT 2.0 system.

Vapotherm Reports Second Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 8, 2023
Managed Care, Health, Medical Devices, Failure, Regulation Fair Disclosure, Table, Telephone, Vapotherm, GAAP, Cyprus Securities and Exchange Commission, Public expenditure, EBITDA, Depreciation, CUSIP, Security (finance), NYSE, Regulation, HVT, Bookkeeping, Eastern Time Zone, Adjustment

In the second quarter of 2023, gross margin increased by 780 basis points over gross margin of 35.0% in the first quarter of 2023.

Key Points: 
  • In the second quarter of 2023, gross margin increased by 780 basis points over gross margin of 35.0% in the first quarter of 2023.
  • Net loss for the second quarter of 2023 was $14.8 million, or $0.29 per share, compared to $42.7 million, or $1.61 per share, in the second quarter of 2022.
  • Net loss per share was based on 50,625,778 and 26,574,027 weighted average shares outstanding for the second quarter of 2023 and 2022, respectively.
  • Adjusted EBITDA was negative $6.4 million for the second quarter of 2023 as compared to negative $20.2 million for the second quarter of 2022.

Vapotherm Reports First Quarter 2023 Financial Results

Retrieved on: 
Wednesday, May 3, 2023
Biotechnology, Medical Devices, Other Health, Health, Medical Supplies, Loss, Failure, Regulation Fair Disclosure, Table, Telephone, Vapotherm, GAAP, Public expenditure, EBITDA, Depreciation, Security (finance), Regulation, HVT, Cryptocurrency, Bookkeeping, Adjustment

In the first quarter of 2023, gross margin increased by 750 basis points over gross margin of 27.5% in the fourth quarter of 2022.

Key Points: 
  • In the first quarter of 2023, gross margin increased by 750 basis points over gross margin of 27.5% in the fourth quarter of 2022.
  • Net loss for the first quarter of 2023 was $18.1 million, or $0.45 per share, compared to $22.9 million, or $0.87 per share, in the first quarter of 2022.
  • Net loss per share was based on 40,608,605 and 26,321,087 weighted average shares outstanding for the first quarter of 2023 and 2022, respectively.
  • Adjusted EBITDA was negative $9.2 million for the first quarter of 2023 as compared to negative $15.3 million for the first quarter of 2022.

Vapotherm Announces Preliminary Revenue for First Quarter of 2022 and Withdraws 2022 Annual Guidance

Retrieved on: 
Wednesday, April 6, 2022
Biotechnology, Other Manufacturing, General Health, Health, Medical Devices, Hospitals, Manufacturing, Other Health, EBITDA, Hospital, Company, Private Securities Litigation Reform Act, Adoption, Gas, Risk, Regulation, Virulence, Patent, NYSE, Oxygen, SEC, Investor relations, CEO, Hypoxemia, Failure, Food, Security (finance), Omicron, Technology, Food and Drug Administration, HVT, COVID-19, U.S. Securities and Exchange Commission, RSV, VAPO, Breathe Me, Regulation Fair Disclosure, Patient, Video game, Pharmaceutical industry, Vapotherm

Vapotherm, Inc. (NYSE: VAPO) (Vapotherm or the Company), today announced preliminary unaudited revenue for the quarter ended March 31, 2022.

Key Points: 
  • Vapotherm, Inc. (NYSE: VAPO) (Vapotherm or the Company), today announced preliminary unaudited revenue for the quarter ended March 31, 2022.
  • The Company also announced withdrawal of its full year 2022 revenue guidance (issued on January 12, 2022 and reiterated on February 24, 2022) together with its full year 2022 gross margin, operating expense and adjusted EBITDA guidance.
  • Preliminary revenue for the first quarter of 2022 is expected to be in the range of $20.5 million to $21.5 million, compared to $32.3 million for the first quarter of 2021.
  • Vapotherm plans to release financial results for the first quarter of 2022 after the close of trading on Wednesday, May 4, 2022.

Vapotherm Reports Preliminary Fourth Quarter and Full Year 2021 Revenue Results

Retrieved on: 
Wednesday, January 12, 2022
Technology, General Health, Health, Other Technology, Patient, Investor relations, Private Securities Litigation Reform Act, SEC, Breathe Me, Gold, COVID-19, NYSE, U.S. Securities and Exchange Commission, CEO, Regulation Fair Disclosure, Review, Regulation, HVT, Gas, Company, Food and Drug Administration, Risk, Hospital, Food, Patent, Hypoxemia, Security (finance), Failure, Investment, VAPO, Pharmaceutical industry, Animal, Vapotherm

Preliminary net revenue for the fourth quarter of 2021 is expected to be approximately $21.8 million, a two-year compounded annual growth rate of approximately 29%.

Key Points: 
  • Preliminary net revenue for the fourth quarter of 2021 is expected to be approximately $21.8 million, a two-year compounded annual growth rate of approximately 29%.
  • Preliminary net revenue for the full year 2021 is expected to be approximately $112.8 million, a two-year compounded annual growth rate of approximately 53%.
  • The Company plans to release its fourth quarter and full year 2021 financial results in late February 2022.
  • These preliminary net revenue results are based on current expectations.

Vapotherm Announces FDA 510(k) Clearance for HVT 2.0 Next Generation Platform

Retrieved on: 
Monday, August 30, 2021
FDA, Medical Devices, Hospitals, Health, Medical Supplies, Company, U.S. Securities and Exchange Commission, Bed, Investor relations, VAPO, Breathe Me, Food, Hospital, NYSE, ICU, Hypoxemia, HVT, Regulation Fair Disclosure, Regulation, Gas, Failure, Food and Drug Administration, Patient, CEO, US Foods, Degenerative disease, COVID-19, Patent, Security (finance), Pharmaceutical industry

Vapotherm, Inc. (NYSE: VAPO), (Vapotherm or the Company), today announced it has received 510(k) clearance from the US Food and Drug Administration for HVT 2.0.

Key Points: 
  • Vapotherm, Inc. (NYSE: VAPO), (Vapotherm or the Company), today announced it has received 510(k) clearance from the US Food and Drug Administration for HVT 2.0.
  • The Company is planning a limited commercial release of HVT 2.0 in the United States in the fourth quarter of 2021.
  • Clearance of HVT 2.0 enables us to provide high velocity therapy to Patients throughout the hospital, which is very important when ICU beds become scarce.
  • We will also use this next generation platform, combined with the Vapotherm Access digital remote Patient monitoring platform, to begin learning how to treat complex lung disease Patients in the home, said Joe Army, President and CEO of Vapotherm.

Havertys To Host Second Quarter 2021 Earnings Conference Call on July 28

Retrieved on: 
Thursday, July 22, 2021
HVT, New York Stock Exchange, Havertys

ATLANTA, July 21, 2021 (GLOBE NEWSWIRE) -- HAVERTYS (NYSE: HVT and HVT.A) will release its second quarter 2021 financial results on Tuesday, July 27, 2021, after the market closes.

Key Points: 
  • ATLANTA, July 21, 2021 (GLOBE NEWSWIRE) -- HAVERTYS (NYSE: HVT and HVT.A) will release its second quarter 2021 financial results on Tuesday, July 27, 2021, after the market closes.
  • The company will host a conference call with investors and analysts on Wednesday, July 28, 2021, at 10:00 a.m.
  • Havertys invites interested parties to listen to the live audiocast of the conference call at its website, havertys.com .A replay will be availableat the website orvia telephone at approximately 1:00 p.m. ETthrough Saturday, August 7, 2021.
  • The number to access the telephone playback is 1-888-203-1112 (access code: 5638660).

Havertys to Present at Shareholder Equity Conference

Retrieved on: 
Monday, June 28, 2021
Finance, Money, Economy, HVT, Havertys, Investor, New York Stock Exchange, Fireside chats

ATLANTA, June 28, 2021 (GLOBE NEWSWIRE) -- HAVERTYS (NYSE: HVT and HVT.A), today announced management will participate in the inaugural Shareholder Equity Conference presented by Asbury Investor Relations and Stockperks.

Key Points: 
  • ATLANTA, June 28, 2021 (GLOBE NEWSWIRE) -- HAVERTYS (NYSE: HVT and HVT.A), today announced management will participate in the inaugural Shareholder Equity Conference presented by Asbury Investor Relations and Stockperks.
  • Havertys will present on Monday, July 12, 2021, at 3:10 p.m.
  • The conference will be held virtually and is set in a fireside chat format and directed to provide access to retail investors.
  • The Company invites interested parties to access a live stream of this presentation at its website, havertys.